Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

628
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
628
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

551
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
551
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

231
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
231
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

93
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
93

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type III intermediate filaments as novel CoAlation targets.

Redox report : communications in free radical research·2026
Same author

Corrigendum to "Alexander disease mutations differentially sensitize glial fibrillary acidic protein (GFAP) to posttranslational modifications and network disruption by oxidants" [Redox Biology 92 (2026) 104103].

Redox biology·2026
Same author

Author Correction: Curing the brain: in search for new astrocyte-specific therapies.

Experimental & molecular medicine·2026
Same author

Lysosomal function, resistance to oxidative stress and repair are compromised by expression of the Alexander disease GFAP R239C mutant.

Free radical biology & medicine·2026
Same author

Curing the brain: in search for new astrocyte-specific therapies.

Experimental & molecular medicine·2026
Same author

Alexander disease mutations differentially sensitize glial fibrillary acidic protein (GFAP) to posttranslational modifications and network disruption by oxidants.

Redox biology·2026

Related Experiment Video

Updated: Aug 2, 2025

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.7K

Alexander disease: the road ahead.

María A Pajares1, Elena Hernández-Gerez1, Milos Pekny2

  • 1Department of Structural and Chemical Biology, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain.

Neural Regeneration Research
|April 14, 2023
PubMed
Summary

Alexander disease, a neurodegenerative disorder, stems from glial fibrillary acidic protein (GFAP) mutations. Research highlights GFAP mutations, astrocyte dysfunction, and experimental models for therapeutic strategies.

Keywords:
astrocytesendoplasmic reticulum stressglial fibrillary acidic protein mutantsmetabolismmisassemblymisfoldingneurodegenerationoxidative stressposttranslational modificationsunfolded protein response

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.3K
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

21.5K

Related Experiment Videos

Last Updated: Aug 2, 2025

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.7K
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.3K
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

21.5K

Area of Science:

  • Neurobiology
  • Cell Biology
  • Genetics

Background:

  • Alexander disease is a rare neurodegenerative disorder linked to mutations in glial fibrillary acidic protein (GFAP).
  • This protein is crucial for astrocyte function and intermediate filament networks.
  • Characteristic Rosenthal fibers form in astrocytes in affected individuals.

Purpose of the Study:

  • To explore the molecular mechanisms underlying GFAP mutations in Alexander disease.
  • To investigate the impact of mutations on GFAP expression, posttranslational modifications, and protein interactions.
  • To evaluate the role of organelle dysfunction and oxidative stress in astrocyte pathology.

Main Methods:

  • Analysis of GFAP mutations and their effects on filament network disruption.
  • Study of GFAP isoforms, posttranslational modifications, and protein-protein interactions.
  • Investigation of astrocyte organelle function, mitochondrial activity, and redox balance.

Main Results:

  • GFAP mutations disrupt the intermediate filament network and can lead to aggregate formation.
  • Altered expression of GFAP isoforms and posttranslational modifications contribute to disease pathology.
  • Mitochondrial dysfunction and oxidative stress exacerbate astrocyte impairment.

Conclusions:

  • GFAP mutations are central to Alexander disease pathogenesis, affecting astrocyte and neuronal function.
  • Understanding these molecular changes is vital for developing targeted therapies.
  • Advancements in experimental models offer hope for future therapeutic strategies.